MAP4K4 impairs energy metabolism in endothelial cells and promotes insulin resistance in obesity by Roth Flach, Rachel J. et al.
University of Massachusetts Medical School 
eScholarship@UMMS 
UMass Metabolic Network Publications UMass Metabolic Network 
2017-06-13 
MAP4K4 impairs energy metabolism in endothelial cells and 
promotes insulin resistance in obesity 
Rachel J. Roth Flach 
University of Massachusetts Medical School 
Et al. 
Let us know how access to this document benefits you. 
Follow this and additional works at: https://escholarship.umassmed.edu/metnet_pubs 
 Part of the Biochemistry Commons, Cell Biology Commons, Cellular and Molecular Physiology 
Commons, and the Molecular Biology Commons 
Repository Citation 
Roth Flach RJ, DiStefano MT, Danai LV, Senol-Cosar O, Yawe JC, Kelly M, Garcia Menendez L, Czech MP. 
(2017). MAP4K4 impairs energy metabolism in endothelial cells and promotes insulin resistance in 
obesity. UMass Metabolic Network Publications. https://doi.org/10.1152/ajpendo.00037.2017. Retrieved 
from https://escholarship.umassmed.edu/metnet_pubs/102 
This material is brought to you by eScholarship@UMMS. It has been accepted for inclusion in UMass Metabolic 
Network Publications by an authorized administrator of eScholarship@UMMS. For more information, please contact 
Lisa.Palmer@umassmed.edu. 
Endothelial MAP4K4 in metabolism 
1 
 1 
 2 
 3 
 4 
MAP4K4 impairs energy metabolism in endothelial cells and 5 
promotes insulin resistance in obesity 6 
 7 
Rachel J. Roth Flach1*, Marina T. DiStefano2, Laura V. Danai3, Ozlem Senol-Cosar2, 8 
Joseph C. Yawe4, Mark Kelly5, Lorena Garcia Menendez, Michael P. Czech 9 
 10 
Program in Molecular Medicine,  11 
University of Massachusetts Medical School, Worcester, MA 01605, USA 12 
 13 
 14 
Author contributions: R.J.R.F. and M.P.C designed research, R.J.R.F., L.V.D., 15 
L.G.M., M.T.D., O. S-C., J.C.Y. and M.K. performed research, and R.J.R.F and M.P.C 16 
wrote the manuscript.  17 
 18 
 19 
 20 
Running title: Endothelial MAP4K4 in metabolism 21 
 22 
 23 
Key words: Endothelial, MAP4K4, obesity, lymphatic, inflammation 24 
 25 
 26 
Classification: Biological Sciences; Medical Sciences 27 
 28 
 29 
 30 
 31 
*Address correspondence to: 32 
 33 
Rachel J. Roth Flach 34 
Pfizer, Inc. 35 
1 Portland St, 307J 36 
Cambridge, MA 02139 37 
e-mail: Rachel.Rothflach@pfizer.com 38 
 39 
 40 
 41 
 42 
 43 
Articles in PresS. Am J Physiol Endocrinol Metab (June 13, 2017). doi:10.1152/ajpendo.00037.2017 
 Copyright © 2017 by the American Physiological Society.
Endothelial MAP4K4 in metabolism 
2 
Abstract 44 
The blood vasculature responds to insulin, influencing hemodynamic 45 
changes in the periphery, which promotes tissue nutrient and oxygen delivery 46 
and thus metabolic function. The lymphatic vasculature regulates fluid and lipid 47 
homeostasis, and impaired lymphatic function can contribute to atherosclerosis 48 
and obesity. Recent studies have suggested a role for endothelial cell (EC) 49 
Mitogen activated protein kinase kinase kinase kinase 4 (Map4k4) in 50 
developmental angiogenesis and lymphangiogenesis as well as atherosclerosis. 51 
Here, we show that inducible EC Map4k4 deletion in adult mice ameliorates 52 
metabolic dysfunction in obesity despite the development of chylous ascites and 53 
a concomitant striking increase in adipose tissue lymphocyte content. Despite 54 
these defects, animals lacking endothelial Map4k4 were protected from skeletal 55 
muscle microvascular rarefaction in obesity, and primary ECs lacking Map4k4 56 
displayed reduced senescence and increased metabolic capacity. Thus, 57 
endothelial Map4k4 has complex and opposing functions in the blood and 58 
lymphatic endothelium post-development. Whereas blood endothelial Map4k4 59 
promotes vascular dysfunction and impairs glucose homeostasis in adult 60 
animals, lymphatic endothelial Map4k4 is required to maintain lymphatic vascular 61 
integrity and regulate immune cell trafficking in obesity. 62 
 63 
 64 
 65 
 66 
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Introduction 67 
Type 2 diabetes (T2D) is associated with impaired glucose homeostasis, insulin 68 
resistance and an increased inflammatory state (16, 35, 43, 46). Though much work has 69 
sought to investigate the mechanisms by which T2D occurs and how to ameliorate this 70 
disease, there is still a lack of mechanistic understanding of the contribution of individual 71 
physiological systems to disease progression. In particular, the vascular endothelium 72 
has been investigated as a contributor to T2D pathology (18, 19, 41). Endothelial cells 73 
line the blood and lymphatic vasculature within every tissue, and the vascular 74 
endothelium has a unique role to communicate nutritional and inflammatory status of 75 
underlying tissue to the systemic circulation by delivering nutrients, hormones and 76 
oxygen (1). Conversely, the lymphatic endothelium regulates fluid balance, intestinal 77 
lipid absorption, and immune function (7, 25). Recent human and mouse genetic studies 78 
have suggested that the endothelium plays a multifaceted role in whole body 79 
metabolism (4, 18, 19, 34, 37).  80 
In obesity the endothelium becomes resistant to the hormone insulin, which 81 
impairs blood flow and thus insulin and nutrient transport to tissues such as skeletal 82 
muscle resulting in increased plasma glucose levels and type 2 diabetes (19, 47). 83 
Furthermore, lymphatic vessels within adipose tissue can become leaky and further 84 
exacerbate obesity by promoting adipogenesis (17, 32). Finally, type 2 diabetes is also 85 
associated with low-grade inflammation in multiple tissues including adipose tissue and 86 
liver (16), which is mediated in part by immune cell recruitment from the peripheral 87 
vasculature (22, 23, 29, 30). Thus, identifying molecular targets within the vasculature 88 
that mediate these dysfunctions are important for improving human health. 89 
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Our laboratory recently demonstrated that inducible, systemic loss of the protein 90 
kinase Mitogen activated protein kinase kinase kinase kinase 4 (Map4k4) in adult obese 91 
mice improved insulin sensitivity and regulated insulin secretion (8, 26). Using 92 
constitutive endothelial-specific knockout animals, we demonstrated that Map4k4 has a 93 
profound and complex role to control lymphatic vascular development (27); however, 94 
inducible endothelial Map4k4 deletion was beneficial in Apoe-/- mice, as Apoe-/- mice 95 
lacking Map4k4 (28) demonstrated reduced atherosclerotic plaque development and 96 
reduced leukocyte recruitment. We thus hypothesized that obese C57BL6/J mice 97 
lacking endothelial Map4k4 might also display reduced obesity-induced adipose tissue 98 
inflammation and therefore improved insulin sensitivity.  99 
The present studies were designed to bypass the developmental phenotype 100 
recently reported in constitutively expressed Cdh5 cre (Ve-Cadherin cre) Map4k4 101 
endothelial-specific knockout mice (27) by generating inducible endothelial-specific 102 
Map4k4 deletion in adult C57BL6/J mice using the tamoxifen-induced Cdh5(PAC)ERT2-103 
cre (44). Interestingly, chow-fed animals displayed no overt phenotype; however, when 104 
challenged with a high fat diet (HFD), inducible endothelial-specific Map4k4 knockout 105 
mice (M4K4 iECKO) displayed a non-significant trend to improved glucose tolerance 106 
and significantly enhanced insulin sensitivity compared with controls. Despite this 107 
metabolic improvement in M4K4 iECKO mice, these animals also displayed lymphatic 108 
defects as noted by chyle leakage in the abdomen (chylous ascites) and increased 109 
immune cell content in epidiymal adipose tissue. Despite these lymphatic defects, 110 
skeletal muscle capillary density was maintained after HFD in M4K4 iECKO mice 111 
compared with controls, and isolated endothelial cells derived from these animals 112 
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displayed enhanced energy metabolism and protection from senescence. Taken 113 
together, these results demonstrate a complex and critical role for endothelial Map4k4 114 
to maintain lymphatic vascular integrity yet promote systemic insulin resistance in 115 
obesity. 116 
 117 
Materials and Methods 118 
 119 
Mouse models: The University of Massachusetts Medical School Institutional Animal 120 
Care and Use Committee approved all of the animal procedures. Map4k4 Flox/Flox 121 
animals and M4K4 iECKO mice (Cdh5(PAC)-CreERT2) were maintained on a pure 122 
C57Bl6/J background after at least 8 backcrosses and have been previously described 123 
(28). At 6-8 weeks of age, male Flox/Flox and Flox/Flox/cre+ littermates were injected 124 
with 1 mg tamoxifen/day in corn oil (Sigma) for 5 days; 2 weeks after tamoxifen 125 
injection, the mice were fed standard chow or high fat diet (60% fat, Research diets 126 
RD12492i) for 16 weeks. Mice were euthanized by CO2 inhalation followed by bilateral 127 
pneumothorax. Mice were fasted for 16 h for GTTs or for 4 h for ITTs. Fasted mice were 128 
i.p. injected with glucose (1 g/kg) or insulin (1 IU/kg). Blood glucose levels were 129 
determined from the tail vein using a Breeze-2 glucose meter (Bayer). No statistical 130 
methods were used to predict sample size, no randomization was performed, and the 131 
investigations were not blinded.  132 
 133 
Miles assay: 4 weeks after tamoxifen injections, mice were injected intravenously (i.v.) 134 
with 1.5% Evans Blue Dye (50 mg/kg) into the tail vein. 30 mins post-injection, mice 135 
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were sacrificed by cervical dislocation and perfused with saline for 10 minutes. Pieces 136 
of inguinal white adipose tissue (WAT), epididymal WAT, lung and liver were excised, 137 
weighed and incubated in formamide overnight at 55°C with shaking to extract the dye. 138 
Absorbance of the extravasated dye was quantified by spectrophotometry at 620 nm 139 
and normalized to tissue weight.  140 
 141 
RNA isolation and quantitative RT-PCR: Total RNA was isolated, cDNA was 142 
prepared, and quantitative RT-PCR was performed as previously described (28).  143 
Primer sequences are detailed in Table 1. 144 
 145 
Immunostaining: Whole mount staining was performed on tissues that had been fixed 146 
in 10% formalin for 2-6 hours. Adipose tissue, skeletal muscle or aortic rings were 147 
blocked overnight in 10% BSA and 0.3% triton X-100 in PBS at 4C, stained overnight 148 
with Isolectin B4 (Life Technologies I21411; 1:40) in 100 mM MgCl2, 100 mM CaCl2, 10 149 
mM MnCl2, and 1%Triton X-100 in PBS at 4C, and washed 3x 20 minutes in 5% BSA, 150 
0.15% triton X-100 in PBS at room temperature. Tissues were mounted in ProLong 151 
Gold (Life Technologies). Whole mount images were visualized in flattened 25 um z-152 
stacks with a Solamere Technology Group modified Yokogawa CSU10 spinning disk 153 
confocal system with a Nikon TE-2000E2 inverted microscope at 10x or 20x. Images 154 
were acquired with MetaMorph Software, version 6.1 (Universal Imaging, Downingtown, 155 
PA). A Zeiss Axiovert 100 inverted microscope with a 5x or 10x objective and AxioCam 156 
HRm camera was used for aortic ring assay images. At least 3 muscle or adipose tissue 157 
images were quantified and averaged for average vascular density per mouse. Images 158 
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were quantified using Image J Analysis Software. Different mice were used for the 159 
analyses of different tissues. 160 
 161 
Senescence Assays:  Primary mouse lung endothelial cells (MLECs) were prepared 162 
by digestion and immune-isolation using CD31 and ICAM-2-coated magnetic beads as 163 
previously described (28). MLECs were used on passage 3 for all experiments. 164 
Senescence was assessed in MLECs that had grown to confluence with the beta 165 
galactosidase senescence assay kit (Cell Signaling) according to manufacturer’s 166 
instructions. Percent positive staining was determined in at least 3 5x fields using image 167 
J software. Nuclei were stained with Hoechst (Sigma), and the entire well was imaged 168 
using the In Cell high content imager and counted using Columbus Image data analysis 169 
software. Percent positive area was normalized to nuclei number. 170 
 171 
Flow Cytometry: The epididymal adipose tissue stromal vascular fraction (SVF) was 172 
isolated by digestion in Hanks balanced salt solution, 2.5% BSA and 2 mg/mL 173 
collagenase for 45 minutes and strained through a 70 μm filter followed by red blood cell 174 
lysis (155 mM NH4Cl, 12 mM NaHCO3, 0.1 mM EDTA).  Cells were blocked with mouse 175 
IgG in FACS buffer (1% BSA/PBS). Cells were stained with antibodies directed towards 176 
F4/80 (APC, ABd serotec), CD11b (Percp 5.5, BD), Siglec F (PE, BD), GR-1 (APC-Cy7, 177 
BD), Ly6c (PE-Cy7, BD), Galectin 3 (FITC, BioLegend), and CD11c (V450, BD) or CD3 178 
(PE-Cy7 or APC-Cy7, BD), CD4 (FITC, BD), CD8 (Percp, BD), CD25 (APC-Cy7, BD), 179 
Foxp3 (PE, BD), CD19 (V450, BD), or NK1.1 (APC, BD). Foxp3 staining was performed 180 
using the Foxp3/Transcription Factor Staining Buffer Set (eBioscience) according to 181 
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manufacturer’s instructions. All antibodies were used at a 1:200 dilution. The data were 182 
collected on an LSRII (BD) and were analyzed with FlowJo software.  Samples were 183 
gated for scatter and single cells. Lymphocyte populations were gated first on low size 184 
and scatter prior to gating for positive staining. Gates were drawn based on 185 
fluorescence minus one (FMO) controls.  A total of at least 100,000 events were 186 
recorded. 187 
 188 
Cellular metabolism measurements: Confluent cell monolayers were obtained by 189 
seeding 60,000 MLECs overnight on 0.2% gelatin-coated Seahorse XF24 tissue culture 190 
plates (Seahorse Biosciences). Seahorse glycostress or mitostress tests were 191 
performed using the standard protocol according to manufacturer’s instructions on an 192 
XF24 Seahorse extracellular flux analyzer. Drug concentrations were as follows: 193 
Glucose (10 mM), Oligomycin (2.5 uM), 2-DG (50 mM), FCCP (1 uM), Antimycin A and 194 
Rotenone (0.87 uM). Oxygen consumption rate (OCR) or extracellular acidification rate 195 
(ECAR) values were normalized to protein content as assessed by BCA assay 196 
(Thermo-Pierce). Each OCR or ECAR value represents an average from duplicate 197 
wells.    198 
 199 
Statistical Analysis: A two-tailed Student’s t-test was used to compare two groups in 200 
GraphPad Prism 6.0 or 7.0. Where indicated, experiments comparing multiple groups 201 
were analyzed with two-way ANOVA with repeated measures. P <0.05 was considered 202 
to be statistically significant, and P = 0.05-0.09 was considered to be a non-significant 203 
trend. Variance was estimated using the standard error of the mean. 204 
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 205 
Results 206 
Inducible EC Map4k4 loss in adult obese mice improves glucose tolerance. 207 
To bypass the lethal effects of Map4k4 deletion in development, Map4k4 was deleted 208 
inducibly with tamoxifen in adult C57Bl6/J mice between 6-8 weeks of age (M4K4 209 
iECKO; Fig. 1A). The deletion pattern of these mice using this protocol has been 210 
previously reported and is nearly 100% after 18 weeks as assessed in primary mouse 211 
lung ECs (MLECs) (28). Inducible Map4k4 deletion in these mice on a chow diet 212 
revealed no obvious phenotypes, and no change in body weight was observed between 213 
genotypes (Fig. 1B). Both Flox/Flox and M4K4 iECKO animals gained weight to a 214 
similar extent on HFD, and no alteration in body weight or tissue weights was observed 215 
and weights of all tissues including subcutaneous adipose tissue (SAT), epididymal 216 
white adipose tissue (eWAT), liver and spleen were unchanged between HFD-fed 217 
control and M4K4 iECKO mice (Fig. 1B-F). 218 
Glucose tolerance and insulin sensitivity were next assessed in chow- and HFD-219 
fed Flox/Flox and M4K4 iECKO mice. In chow-fed Flox/Flox and M4K4 iECKO animals, 220 
no alterations were observed in glucose tolerance or insulin sensitivity (Fig. 1G-H). 221 
However, after HFD, Map4k4 iECKO animals demonstrated a non-significant trend to 222 
improved glucose tolerance compared with Flox/Flox controls (Fig. 1G) and a significant 223 
improvement in HFD-induced insulin resistance (Fig. 1H). We have previously reported 224 
that mice inducibly lacking whole body Map4k4 had dramatic reductions in insulin levels 225 
after HFD, which contributed to improvements in insulin sensitivity (26). Interestingly, a 226 
non-significant trend to reduced insulin levels was also observed in M4K4 iECKO mice 227 
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after HFD compared with Flox/Flox controls (Table 2), suggesting that these animals 228 
are in fact less insulin resistant than control littermates. Taken together, these data 229 
suggest that M4K4 iECKO mice on HFD demonstrate enhanced insulin sensitivity 230 
compared with control Flox/Flox littermates. 231 
Reduced expression of inflammation genes in liver of HFD-fed M4K4 iECKO 232 
mice. The intriguing improvement in insulin sensitivity in M4K4 iECKO mice suggested 233 
that M4K4 expression within the vasculature was detrimental to metabolic homeostasis. 234 
We had previously demonstrated that endothelial Map4k4 promoted vascular 235 
inflammation in atherosclerosis by promoting leukocyte recruitment (28). Thus, we 236 
hypothesized that similar mechanisms may be at play in obesity, and assessed whether 237 
loss of endothelial Map4k4 ameliorated HFD-induced inflammation. 238 
Histological assessment of liver from Flox/Flox and M4K4 iECKO mice revealed 239 
no remarkable differences between genotypes after HFD (Fig. 2A). However, reduced 240 
mRNA expression of adhesion molecule Icam-1 was observed, and there was a non-241 
significant trend to reductions in levels of adhesion molecules Vcam-1, and Selp as well 242 
as immune cell marker F4/80 in whole liver of HFD-fed iECKO mice compared with 243 
controls (Fig. 2B,C), which is consistent with previous observations that endothelial 244 
Map4k4 promotes immune cell recruitment and inflammation (28).  245 
HFD-induced chylous ascites and eWAT immune cell content in M4K4 246 
iECKO mice. Visual inspection, flow cytometry assessment and histological 247 
assessment of eWAT from chow-fed control and M4K4 iECKO mice did not reveal any 248 
significant changes in appearance or immune cell content (Figure 3 and not shown). 249 
However, chylous ascites was observed in approximately 50% of HFD-fed M4K4 iECKO 250 
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mice (Fig. 3A). In addition, the HFD-fed M4K4 iECKO mice displayed a striking increase 251 
in adipose tissue immune cell infiltration in eWAT after HFD, even in animals where no 252 
noticeable chyle leakage was present (Fig. 3B). This observation was surprising 253 
because increased eWAT inflammation in obesity is associated with glucose intolerance 254 
and insulin resistance in humans and in mice (16), and M4K4 iECKO mice displayed 255 
enhanced insulin sensitivity on HFD (Fig. 1G-H). This phenotype seemed to be confined 256 
to eWAT, as retroperitoneal white adipose tissue (rWAT), mesenteric WAT (mWAT), 257 
subcutaneous WAT (SAT), and intrascapular brown adipose tissue (BAT) histology 258 
revealed no significant alterations in tissue morphology between the genotypes after 259 
HFD (Fig. 3C). 260 
Numerous studies have demonstrated that macrophages are the predominant 261 
immune cell type in obese AT and accumulate in crown-like structures that surround 262 
adipocytes (45, 48). However, the inflammatory phenotype observed within the M4K4 263 
iECKO eWAT was not characteristic of crown-like structures and instead resembled 264 
dense cell clusters with small, dark nuclei (Fig. 3B). This observation coupled with the 265 
chyle leakage observed in M4K4 iECKO mice (Fig. 3A) suggested that this cell 266 
population might be atypical. To elucidate what cell types comprised the immune cells 267 
within the adipose tissue, the stromal vascular fraction (SVF) was isolated from eWAT, 268 
and flow cytometry was performed. Interestingly, no significant differences in the SVF 269 
CD11b+/F4/80+ macrophage populations were observed between Flox/Flox and M4K4 270 
iECKO mice, nor were there differences in the CD11b+/F4/80+/Cd11c+ pro-271 
inflammatory macrophage population (Fig. 4A, C). Furthermore, mRNA expression of 272 
macrophage markers F4/80, Itgam, Itgax and Cd68 and macrophage-derived cytokines 273 
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Ccl-2, Il-1β, Il-6, and Tnf-α were not altered in control and iECKO HFD-fed mice (Fig. 274 
4D). 275 
Lymphocyte populations were then assessed within eWAT of Flox/Flox and 276 
M4K4 iECKO mice. Flow cytometry of eWAT-derived SVF revealed a significant 277 
increase in lymphocyte populations, as a 72% increase in Cd19+ B lymphocytes (3% 278 
vs. 5.1% of SVF for Flox/Flox or M4K4 iECKO mice, respectively, Fig. 4E) and a 47% 279 
increase in total Cd3+ T lymphocyte content (12.5 vs. 18.4% of SVF for Flox/Flox or 280 
M4K4 iECKO mice, respectively, Fig. 4E) was observed in M4K4 iECKO mice. Further 281 
assessment of T lymphocyte subsets within SVF revealed that pro-inflammatory Cd8+ 282 
as well as anti-inflammatory Cd4+ and Treg (Cd25+/Foxp3+) lymphocyte populations 283 
were significantly enhanced in M4K4 iECKO SVF by a similar extent (Fig. 4B, E). 284 
Analysis by qRT-PCR of whole eWAT also demonstrated a significant enhancement of 285 
T lymphocyte markers Cd4 and Cd8 and a non-significant trend to an increase in Foxp3 286 
gene expression (p=0.09) in M4K4 iECKO eWAT after HFD, but interestingly there was 287 
no concomitant increase in T-cell derived cytokines Il-4, Il-10, Ifn-γ, Il-13, Il-17, or IL-21 288 
(Fig. 4F). These data suggest that the lymphocyte accumulation in M4K4 iECKO eWAT 289 
after HFD may be a passive accumulation of naïve lymphocytes a consequence of 290 
chyle leakage into the abdominal cavity. These data also suggest that although chyle 291 
leakage is only visually present in 50% of animals, there is likely lymphatic leakage and 292 
dysfunction in all of the M4K4 iECKO animals, even if no chyle is observed by eye.  293 
Maintained blood vascular integrity and reduced microvascular rarefaction 294 
in skeletal muscle of M4K4 iECKO mice. Lymphatic dysfunction promotes obesity 295 
and is associated with metabolic disease in mice (17, 32). Thus, it is intriguing that 296 
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despite their lymphatic chyle leakage defects, M4K4 iECKO mice are glucose tolerant 297 
and insulin sensitive compared with controls. However, the VE Cadherin promoter used 298 
to generate M4K4 iECKO mice deletes genes in both blood and lymphatic endothelial 299 
compartments (36). Thus, we cannot exclude the possibility that the improved 300 
metabolism in the M4K4 iECKO mice is due to changes in blood vascular ECs. Previous 301 
studies using cell culture models demonstrated that Map4k4 loss reduces endothelial 302 
cell barrier function (24, 28). Thus, vascular permeability was assessed in vivo by 303 
injecting Evan’s blue dye i.v. into chow fed Flox/Flox and Map4k4 iECKO mice, and no 304 
differences were observed in the amount of dye that had leaked into adipose tissue, 305 
liver or lung between genotypes (Fig. 5A-D). Thus, Map4k4 may not be critical to 306 
maintain baseline vascular permeability in healthy mice. Angiogenesis and blood 307 
vascular function is critical for metabolic homeostasis, as humans and animals with 308 
angiogenic defects display metabolic dysfunction, and angiogenesis is critical to proper 309 
adipose tissue expansion and health (5, 6, 14, 15, 38). To assess angiogenic potential, 310 
aortic ring angiogenesis assays were performed; however, no difference was observed 311 
in the number of isolectin B4-stained sprouts from Flox/Flox and M4K4 iECKO aortas 312 
(Fig. 5E-F).  313 
Capillary density was next assessed in tissues of the HFD-fed Flox/Flox and 314 
M4K4 iECKO mice. eWAT was isolated, and whole-mount samples were 315 
immunostained with isolectin B4 as a measure of capillary density. However, only a 316 
non-significant trend in isolectin B4 staining was observed in HFD-fed M4K4 iECKO 317 
mice (Fig. 5G-H). In skeletal muscle, capillary density is paramount for insulin-mediated 318 
hemodynamic changes and reflects insulin sensitivity, and a loss of capillary density, or 319 
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capillary rarefaction, occurs in obesity (4, 13). To assess this, soleus muscle was 320 
isolated from chow and HFD-fed Flox/Flox and M4K4 iECKO mice and stained whole-321 
mount with isolectin B4. In chow-fed mice, there was no difference in microvascular 322 
density between genotypes (Fig. 5I-J). However, HFD-fed M4K4 iECKO animals were 323 
resistant to capillary rarefaction compared with controls (Fig. 5I-J). These observations 324 
are reminiscent to what has been previously reported in the retina using the constitutive 325 
Cdh5 promoter (27). This protection from capillary rarefaction could explain why M4K4 326 
iECKO mice are insulin sensitive, as capillary rarefaction is associated with insulin 327 
resistance and metabolic disease (4, 34).       328 
Because loss of endothelial Map4k4 promoted enhanced lymphatic vascular and 329 
blood vascular density phenotypes in development and protected against capillary 330 
rarefaction in HFD (Fig. 5) (27), we hypothesized that Map4k4 may affect EC growth. 331 
Indeed, our previous reports describe that ECs derived from M4K4 iECKO mice 332 
displayed enhanced proliferation, which is relevant in development, tissue expansion, 333 
and response to injury (27). In normal, uninjured tissues, microvascular ECs are mostly 334 
quiescent; however, they are subject to senescence in obese states and with aging 335 
(42). To assess whether replicative senescence was altered by loss of Map4k4, primary 336 
MLECs were isolated from chow-fed Flox/Flox or M4K4 iECKO mice that had been 337 
injected with tamoxifen as demonstrated in Fig. 1A. ECs senesce rapidly in culture (11); 338 
thus, endogenous β-galactosidase (β-gal) activity was assessed at passage 3 in 339 
confluent MLECs. Whereas Flox/Flox MLECs demonstrated abundant β-gal staining 340 
consistent with senescence, M4K4 iECKO MLECs displayed a 55% reduction in 341 
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endogenous β-gal activity as assessed by stained area and normalized to total number 342 
of nuclei (Fig. 6 A-B).  343 
Enhanced mitochondrial and glucose metabolism in ECs Lacking Map4k4. 344 
Recent studies have demonstrated that glycolysis and fatty acid oxidation are critical for 345 
EC proliferation (10, 33). The reduced senescence observed in M4K4 iECKO MLECs 346 
(Fig. 6A-B) suggested that these cells might be more metabolically active than Flox/Flox 347 
controls (49). Our laboratory originally identified Map4k4 as a negative regulator of 348 
glucose uptake in adipocytes (40); thus, ECs lacking Map4k4 may also display 349 
increased glycolysis and metabolic flux. Mitochondrial and glycolytic function was 350 
assessed in Flox/Flox and M4K4 iECKO MLECs using the Seahorse extracellular flux 351 
analyzer. In a mitochondrial stress test, the basal oxygen consumption rate (OCR) and 352 
mitochondrial coupling efficiency were similar between genotypes (Fig. 6C-D). However, 353 
when the mitochondria were uncoupled with Carbonyl cyanide-4-354 
(trifluoromethoxy)phenylhydrazone (FCCP), a dramatic increase in oxygen consumption 355 
was observed indicating increased spare capacity of the mitochondria in M4K4 iECKO 356 
MLECs compared with Flox/Flox controls (Fig. 6C-D). When subjected to a glycolysis 357 
stress test, no changes in acidification rates in response to glucose alone were 358 
observed, suggesting that basal glycolysis was similar between genotypes (Fig. 6E-F). 359 
However, when M4K4 iECKO MLECs were treated with oligomycin to inhibit 360 
mitochondrial ATP production, the increased acidification rate demonstrated a non-361 
significant trend to enhanced glycolytic capacity, as well as a significant increase in 362 
glycolytic reserve (Fig. 6E-F). These data suggest that loss of Map4k4 in ECs allows for 363 
a better response to energy stress and could therefore contribute to the improved 364 
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metabolic phenotype and the protection from capillary rarefaction that was observed in 365 
M4K4 iECKO mice despite lymphatic abnormalities.  366 
 367 
Discussion 368 
These studies reveal a complex role of endothelial protein kinase Map4k4 to 369 
promote whole-body metabolic dysfunction. Using tamoxifen-inducible 370 
Cdh5(PAC)ERT2-cre to delete endothelial Map4k4 in adult C57Bl6/J mice, we observed 371 
that loss of endothelial Map4k4 improved insulin sensitivity in obesity (Fig. 1). Mice 372 
lacking endothelial Map4k4 displayed unaltered adipose tissue size or hepatic lipid 373 
content but reduced inflammatory gene expression in liver (Fig. 2). Loss of endothelial 374 
Map4k4 also caused chyle leakage and immune cell infiltration in eWAT (Figs. 3-4), 375 
presumably due to lymphatic vascular deficiencies. These phenotypes seem to 376 
counteract each other; while Map4k4 expression is detrimental in the blood vasculature, 377 
it is required for normal lymphatic vascular function. These observations are consistent 378 
with previous observations in development, in which loss of endothelial Map4k4 through 379 
use of constitutively expressed Ve Cadherin-Cre led to postnatal lethality due to fluid 380 
leakage and chylothorax (27). These observations are also consistent with our previous 381 
study in Apoe-/- mice, in which mice lacking endothelial Map4k4 were protected from 382 
atherosclerosis development (28). Chyle leakage was not observed in Apoe-/- mice 383 
lacking endothelial Map4k4 after deletion with tamoxifen using the same cre driver 384 
(Cdh5(PAC) Ve-ERT2) and injection protocol described here; however, the lymphatics 385 
in Apoe-/- mice are dysfunctional, which could account for this difference (20, 21, 39).  386 
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Though apparent lymphatic defects were observed in M4K4 iECKO mice, ECs 387 
derived from these animals remarkably demonstrated improved metabolic 388 
characteristics (Figs. 3, 6). This complex metabolic phenotype observed in M4K4 389 
iECKO mice after HFD may be explained by examining the blood and lymphatic 390 
vascular systems as independent systems: though loss of Map4k4 is detrimental to the 391 
lymphatic vascular system, it could be beneficial to the blood vascular system. Recent 392 
studies have demonstrated that glycolysis and fatty acid oxidation are critical for blood 393 
vessel angiogenesis and EC proliferation (10, 33), and we demonstrate here that 394 
primary ECs lacking Map4k4 are resistant to senescence in culture and display 395 
enhanced glycolytic and mitochondrial respiration (Fig. 6). The increase in endothelial 396 
metabolism and reduced senescent phenotype is consistent with previously published 397 
observations describing enhanced proliferation in ECs lacking Map4k4 (27). These 398 
observations could partially explain why mice lacking endothelial Map4k4 were resistant 399 
to capillary rarefaction in obesity (Fig. 5), which likely contributes to the improvement 400 
observed in insulin sensitivity in HFD-fed M4K4 iECKO mice (Fig. 1). These data more 401 
broadly suggest that the improved metabolic phenotype in M4K4 iECKO mice may be 402 
due to ameliorating the detrimental effects of obesity on the blood vasculature. One 403 
limitation to the interpretation of these metabolic data from isolated MLECs is that these 404 
cultures represent a mixed population of lymphatic and blood ECs as they were isolated 405 
using the pan-endothelial cell marker CD31. Future studies will separate out 406 
phenotypes within the lymphatic and blood EC populations to address mechanistically 407 
how Map4k4 regulates EC specification and function. 408 
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Chyle leakage can reportedly cause obesity; however, M4K4 iECKO mice 409 
displayed similar weights as their Flox/Flox littermates (17, 31). Although not all M4K4 410 
iECKO mice displayed visible chyle leakage after HFD, it is likely that all displayed 411 
some degree of lymphatic dysfunction, as pathophysiological changes in lymphatic 412 
vascular integrity can occur even if chyle leakage is not visible (17, 32). Furthermore, 413 
despite chyle leakage, HFD-fed M4K4 iECKO mice demonstrated improved insulin 414 
sensitivity (Fig. 1). One might expect that in the setting of dysfunctional lymphatic 415 
vessels that lipid absorption from the intestine may be compromised in M4K4 iECKO 416 
mice, which could contribute to the improved metabolic function in these animals. 417 
Though excreted lipids were not examined, no alteration in plasma triglyceride or NEFA 418 
content was observed between M4K4 iECKO mice and control littermates (Table 1); 419 
furthermore, no change in weight or adiposity was observed. Future studies will be 420 
conducted using Prox-1 ERT2 cre mice to delete Map4k4 in the lymphatic endothelium, 421 
although these animals do have some cre expression in non-lymphatic tissues. (2). 422 
Alternatively, Cx40-CreERT2 animals could be used to delete Map4k4 in arterial 423 
endothelium only (3); these animal models will be critical to understand the contribution 424 
of the blood vs. lymphatic endothelium to the metabolic phenotype that was observed 425 
here.  426 
In conclusion, we have demonstrated a complex role for protein kinase Map4k4 427 
in developed vasculature to mediate the responses to high fat diet and thus regulate 428 
glucose homeostasis in adult animals. Furthermore, these data suggest that Map4k4 is 429 
not only required for vascular development, but also plays a significant role in vascular 430 
inflammation and remodeling in pathology in adulthood. As the complexities of signaling 431 
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cascades are beginning to be understood in the blood vs. lymphatic vascular 432 
endothelium, future studies assessing the contribution of these metabolic signaling 433 
pathways in blood vs. lymphatic vascular compartments will provide great insight into 434 
the mechanisms by which the vasculature contributes to glucose homeostasis and 435 
insulin signaling in T2D. 436 
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Figure Legends 613 
 614 
Figure 1. Improved glucose tolerance in the context of no change in body 615 
weight in HFD-fed M4K4 iECKO mice. A. Tamoxifen injection and deletion 616 
scheme of endothelial Map4k4. B-F. Mice were fed chow or HFD for 16 weeks 617 
starting 2 weeks post-tamoxifen injections. B. Weight curves of chow and HFD-618 
fed Flox/Flox and M4K4 iECKO mice (N=9-11). C-F. Tissue weights of HFD-fed 619 
Flox/Flox and M4K4 iECKO mice. C. SAT, D. eWAT, E. Liver, F. Spleen (N=9-620 
11). G. Blood glucose levels during a glucose tolerance test. H. Percent glucose 621 
remaining during an insulin tolerance test. (ANOVA *; p<0.05, N=8-9 chow, 13-15 622 
HFD). 623 
 624 
Figure 2. Reduced expression of genes encoding proteins in inflammation 625 
pathways in HFD-fed M4K4 iECKO livers. Flox/Flox or M4K4 iECKO mice 626 
were fed HFD for 16 weeks starting 2 weeks post-tamoxifen injections. A. 627 
Representative H&E stained histological liver sections of at least 5 mice per 628 
genotype. Scale bars represent 100 um. B-C. Whole liver was isolated, and 629 
quantitative rtPCR was performed. B. leukocyte adhesion moecules, C. 630 
leukocyte markers (*; p<0.05, N=8-9). 631 
 632 
Figure 3. Chyle leakage and eWAT inflammation in HFD-fed M4K4 iECKO 633 
mice. Flox/Flox or M4K4 iECKO mice were fed chow or HFD for 16 weeks 634 
starting 2 weeks post-tamoxifen injections. A. Representative image of HFD-fed 635 
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M4K4 iECKO mouse displaying chyle in the abdominal cavity. B. H&E staining of 636 
eWAT from Flox/Flox or M4K4 iECKO mice after chow or HFD. C. H&E staining 637 
of SAT, rWAT, mWAT and intrascapular BAT from Flox/Flox or M4K4 iECKO 638 
mice. Scale bar represents 100 um. Images are representative of at least 5 639 
animals per genotype. 640 
 641 
Figure 4. Lymphocyte accumulation in adipose tissue of HFD-fed M4K4 642 
iECKO mice. A-F. Flox/Flox or M4K4 iECKO mice were fed chow or HFD for 16 643 
weeks starting 2 weeks post-tamoxifen injections. Flow cytometry was performed 644 
from HFD-fed Flox/Flox or M4K4 iECKO mouse SVF. A-B. Representative flow 645 
cytometry panels. A. Cd11b and F4/80-positive macrophages. B. Cd3+ and Cd4 646 
or Cd8 positive lymphocytes. C. Quantitation of flow cytometry for Cd11b and 647 
F4/80-positive macrophages or Cd11b, F4/80 and Cd11c-positive macrophages 648 
as a percentage of cells in SVF (N=8-12). D. qRT-PCR for macrophage marker 649 
genes and macrophage-derived cytokines from whole adipose tissue as 650 
normalized to 36b4 (N=8-11). E. Quantitation of flow cytometry for Cd3, Cd4-, 651 
Cd8-, Treg (foxp3+/Cd25+) and Cd19- positive lymphocytes as a percentage of 652 
cells in SVF (*; p<0.05, **; p<0.005, N=3-6, 7-11). F. qRT-PCR for lymphocyte 653 
marker genes and lymphocyte-derived cytokines from whole adipose tissue as 654 
normalized to 36b4 (*; p<0.05, N=8-11). 655 
 656 
Figure 5. Protection from capillary rarefaction in skeletal muscle of M4K4 657 
iECKO mice. Mice were fed chow (A -F, I-J) or HFD (G-H, I-J) for 16 weeks 658 
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starting 2 weeks post-tamoxifen injections. A-D. Chow-fed mice were injected i.v. 659 
with Evans blue dye for one hour, dye was perfused out with PBS, extracted from 660 
tissues overnight, and assessed spectrophotometrically (N=5-9). E-J Tissues 661 
were stained with isolectin B4 as a measure of vascular density. E-F. Aortas 662 
were isolated, embedded in collagen, and treated with Vegf-A. E. Representative 663 
images. Scale bar represents 250 um. F. Quantification of the average number of 664 
iB4-positive sprouts after 6 days (N=10-11, average of 7-16 technical replicates 665 
per animal). G-H. eWAT was isolated and stained with iB4. G. Representative 666 
images of HFD-fed Flox/Flox an M4K4 iECKO eWAT. Scale bar represents 100 667 
um. H. Quantitation of iB4-stained area (N=8-9). I-J. Soleus muscle was isolated 668 
and stained with iB4. I. Representative images of chow-fed (upper) and HFD-fed 669 
(lower) Flox/Flox and M4K4 iECKO soleus muscle. Scale bars represent 100 um. 670 
J. Quantitation of iB4-stained area (*; p<0.05, N=5-8). 671 
 672 
Figure 6. Reduced senescence and enhanced metabolism in ECs lacking 673 
Map4k4. A-F. Primary MLECs were derived from chow-fed Flox/Flox or M4K4 674 
iECKO mice. A-B. Confluent MLECs were stained for endogenous β-675 
galactosidase activity and normalized to nuclei number as measured by Hoechst 676 
staining. A. Representative image; scale bar represents 100 um. B. Quantitation 677 
of stained area (**; p<0.005, N=9-10). C. Oxygen consumption rate profile of 678 
MLEC mitochondrial respiration. Vertical lines indicate the time of addition of 679 
oligomycin, FCCP, or antimycin A and rotenone. D. Quantitation of mitochondrial 680 
respiration; values are normalized to protein content (*; p<0.05, N=5). E. 681 
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Extracellular acidification rate profile demonstrating glycolytic function in MLECs. 682 
Vertical lines indicate the time of glucose, oligomycin, and 2-DG addition. F. 683 
Quantitation of glycolytic function; values are normalized to protein content (*; 684 
p<0.05, N=7).  685 
 686 
 687 
Table 1. RT-PCR primer sequences. 688 
Gene Forward Reverse 
F4/80 CCCCAGTGTCCTTACAGAGTG GTGCCCAGAGTGGATGTCT 
Cd68 CCATCCTTCACGATGACACCT GGCAGGGTTATGAGTGACAGTT 
Ccl-2 TTAAAAACCTGGATCGGAACCAA GCATTAGCTTCAGATTTACGGGT 
36b4 TCCAGGCTTTGGGCATCA CTTTATCAGCTGCACATCACTCAGA 
Itgam ATGGACGCTGATGGCAATACC TCCCCATTCACGTCTCCCA 
Itgax CTGGATAGCCTTTCTTCTGCTG GCACACTGTGTCCGAACTCA 
Il-1b GCAACTGTTCCTGAACTCAACT ATCTTTTGGGGTCCGTCAACT 
Il-6 TAGTCCTTCCTACCCCAATTTCC TTGGTCCTTAGCCACTCCTTC 
Cd3 AGTGCAGTTCGGGAACAGAAG GATTGGCTACTCTGCTGGGT 
Cd4 TCACCTGGAAGTTCTCTGACC GGAATCAAAACGATCAAACTGCG 
Cd8 CCGTTGACCCGCTTTCTGT CGGCGTCCATTTTCTTTGGAA 
Foxp3 GGTACACCCAGGAAAGACAGC AAGACCTTCTCACAACCAGGC 
Il-4 GGTCTCAACCCCCAGCTAGT GCCGATGATCTCTCTCAAGTGAT 
Il-10 GCTCTTACTGACTGGCATGAG CGCAGCTCTAGGAGCATGTG 
Ifng ATGAACGCTACACACTGCATC CCATCCTTTTGCCAGTTCCTC 
Il-13 CCTGGCTCTTGCTTGCCTT GGTCTTGTGTGATGTTGCTCA 
Il-17 TCAGCGTGTCCAAACACTGAG CGCCAAGGGAGTTAAAGACTT 
Il-21 GGACCCTTGTCTGTCTGGTAG TGTGGAGCTGATAGAAGTTCAGG 
Pepck CTGCATAACGGTCTGGACTTC CAGCAACTGCCCGTACTCC 
G6pc CGACTCGCTATCTCCAAGTGA GTTGAACCAGTCTCCGACCA 
Gck TGAGCCGGATGCAGAAGGA GCAACATCTTTACACTGGCCT 
Fasn GGAGGTGGTGATAGCCGCTAT TGGGTAATCCATAGAGCCCAG 
Cidec ATCAGAACAGCGCAAGAAGA CAGCTTGTACAGGTCGAAGG 
Cidea TGACATTCATGGGATTGCAGAC GGCCAGTTGTGATGACTAAGAC 
Cd14 CTCTGTCCTTAAAGCGGCTTAC GTTGCGGAGGTTCAAGATGTT 
Ccl-3 TTCTCTGTACCATGACACTCTGC CGTGGAATCTTCCGGCTGTAG 
Ccl-5 TCGAGTGACAAACACGACTGC GCTGCTTTGCCTACCTCTCC 
Tnf-a CAGGCGGTGCCTATGTCTC CGATCACCCCGAAGTTCAGTAG 
Icam-1 GTGATGCTCAGGTATCCATCCA CACAGTTCTCAAAGCACAGCG 
Vcam-1 AGTTGGGGATTCGGTTGTTCT CCCCTCATTCCTTACCACCC 
Endothelial MAP4K4 in metabolism 
28 
Sele ATGAAGCCAGTGCATACTGTC CGGTGAATGTTTCAGATTGGAGT 
Selp CATCTGGTTCAGTGCTTTGATCT ACCCGTGAGTTATTCCATGAGT 
 689 
Table 2. Plasma analysis. 690 
 Flox/Flox M4K4 iECKO 
Insulin (ng/mL) 4.22 ± 0.63 2.93 ± 0.22 $ 
NEFA (nmol/L) 0.37 ± 0.07 0.29 ± 0.07 
Triglycerides  0.90 ± 0.09 1.26 ± 0.32 
 691 
Table 2. Flox/Flox and M4K4 iECKO mice were fed HFD for 16 weeks. Animals 692 
were fasted overnight, and plasma insulin, non-esterified fatty acids (NEFA), and 693 
triglyceride levels were assessed ($; p=0.06, N=3-8).  694 
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